Get started
Author

David Blake

Observed names: Blake, David, D. Blake, David G Blake, David G. BLAKE, David G. Blake, G. David BLAKE
ORCID: 0000-0002-8367-3256
Observed ORCID: 0000-0002-8367-3256
OpenAlex ID: A5066645885
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)
2002 · Steven J. McClue, David Blake, et al. · International Journal of Cancer · 366
PDF
Discovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents
2010 · Shudong Wang, Gary Griffiths, et al. · Chemistry & Biology · 107
Regulation of human γ-glutamylcysteine synthetase: co-ordinate induction of the catalytic and regulatory subunits in HepG2 cells
1997 · C. Diane GALLOWAY, G. David BLAKE, et al. · Biochemical Journal · 105
PDF
Discovery ofN-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors
2010 · Shudong Wang, Carol A. Midgley, et al. · Journal of Medicinal Chemistry · 102
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer
2020 · Sheelagh Frame, Chiara Saladino, et al. · PLoS ONE · 94
PDF
A Quantitative Study of the in Vitro Binding of the C-Terminal Domain of p21 to PCNA: Affinity, Stoichiometry, and Thermodynamics
2000 · Daniella I. Zheleva, Nikolai Z. Zhelev, et al. · Biochemistry · 89
Overexpression of the regulatory subunit of γ-glutamylcysteine synthetase in HeLa cells increases γ-glutamylcysteine synthetase activity and confers drug resistance
1999 · Sarah R. TIPNIS, David G. BLAKE, et al. · Biochemical Journal · 72
PDF
High Throughput Screens Yield Small Molecule Inhibitors of Leishmania CRK3:CYC6 Cyclin-Dependent Kinase
2011 · Roderick G. Walker, Graeme Thomson, et al. · PLoS neglected tropical diseases · 35
PDF
Design, Synthesis, and Evaluation of 2-Methyl- and 2-Amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as Ring-Constrained 2-Anilino-4-(thiazol-5-yl)pyrimidine Cyclin-Dependent Kinase Inhibitors
2010 · Neil A. McIntyre, Campbell McInnes, et al. · Journal of Medicinal Chemistry · 35
Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells
2022 · Rong Chen, Yuling Chen, et al. · Leukemia · 30
PDF
Cooperative binding of Tn3 resolvase monomers to a functionally asymmetric binding site
1995 · David G. Blake, Martin R. Boocock, et al. · Current Biology · 28
PDF
Abstract 2814: Potent and selective small molecule inhibitors of polo-like kinase 1: Biological characterization
2012 · Sheelagh Frame, Claire Aspinall, et al. · Cancer Research · 19
The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1
2018 · Russell J. Pearson, David G. Blake, et al. · Cell chemical biology · 17
PDF
Regulation of γ-glutamylcysteine synthetase regulatory subunit (GLCLR) gene expression: identification of the major transcriptional start site in HT29 cells
1999 · Diane C Galloway, David G Blake, et al. · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · 17
Abstract CT037: Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)
2018 · Khanh T. Do, Nicole Chau, et al. · Cancer Research · 12
Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.
2016 · Sara M. Tolaney, John Frederick Hilton, et al. · Journal of Clinical Oncology · 11
CYC065, potential therapeutic agent for AML and MLL leukaemia
2015 · Sheelagh Frame, Chiara Saladino, et al. · Clinical Lymphoma Myeloma & Leukemia · 6
Abstract LB-202: Responses to sequential sapacitabine and seliciclib in patients with BRCA-deficient solid tumors.
2013 · Geoffrey I. Shapiro, John Hilton, et al. · Cancer Research · 6
Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)
2020 · K.T. Do, K. Frej, et al. · European Journal of Cancer · 5
Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS
2019 · Gautam M. Borthakur, Tapan M. Kadia, et al. · Blood · 4
Abstract 1650: CYC065, a novel CDK2/5/9 inhibitor: detailed mechanistic studies, determinants of sensitivity and synergistic combinations
2015 · Chiara Saladino, Sheelagh Frame, et al. · Cancer Research · 4
Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 mutations
2019 · Tanya Keenan, David Liu, et al. · Cancer Research · 3
Abstract 4178: The novel PLK1 inhibitor, CYC140: Identification of pharmacodynamic markers, sensitive target indications and potential combinations
2017 · Sylvie Moureau, Craig MacKay, et al. · Cancer Research · 3
Abstract B182: Molecular basis for clinical development of the novel CDK2/9 inhibitor CYC065 in oncology
2015 · Craig MacKay, Sheelagh Frame, et al. · Molecular Cancer Therapeutics · 3
An Integrative “Omics” Approach, for Identification of Bona Fides PLK1 Associated Biomarker in Esophageal Adenocarcinoma
2019 · Nousheen Bibi, Sajid Rashid, et al. · Current Cancer Drug Targets · 2
Works count: 41
Citation count: 1,181
H-index: 14
I10-index: 16
Year
Topic
Type